Evidence map›Paper›PMID 42738789›Full record

ReviewMolecules (Basel, Switzerland)2026

Safety and Efficacy of Natural and Conventional Psychiatric Treatments: A Comparative Review of Mushroom-Derived Compounds and Medicinal Plants in the Management of Mental Disorders.

Katarzyna Gawłowska, Katarzyna Kaja Nowakowska, Julia Wiktoria Makówka, Wojciech Bajurny, Magdalena Patrycja Góral, Agata Bocheńska, Szymon Dariusz Kopecki, Weronika Marta Grodzińska, Agnieszka Chłopaś-Konowałek

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katarzyna GawłowskaScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.ORCID 0009-0001-1183-7872
Katarzyna Kaja NowakowskaThe Faculty of Medicine and Health Sciences, Collegium Medicum of the University of Zielona Gora, Zyty 28, 65-046 Zielona Gora, Poland.
Julia Wiktoria MakówkaScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.
Wojciech BajurnyScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.ORCID 0009-0009-3444-9627
Magdalena Patrycja GóralScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.
Agata BocheńskaScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.
Szymon Dariusz KopeckiScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.
Weronika Marta GrodzińskaScientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, J. Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland.ORCID 0009-0006-7246-3946
Agnieszka Chłopaś-KonowałekDepartment of Forensic Medicine, Division of Molecular Techniques, Wroclaw Medical University, Sklodowskiej-Curie 52, 50-369 Wroclaw, Poland.ORCID 0000-0003-2814-8114

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard pharmacotherapy for mental disorders, including depression and anxiety, is supported by extensive clinical validation and international treatment guidelines. However, it is frequently associated with limitations such as adverse side effects, low patient adherence, and the risk of relapse. Conventional approaches rely primarily on antidepressants, anxiolytics, mood stabilizers, neuroleptics, and stimulants, which modulate monoaminergic, GABAergic, and dopaminergic neurotransmission. Recently, preclinical and emerging clinical studies have suggested that selected natural substances-specifically mushroom-derived compounds and well-established medicinal plants-may offer complementary therapeutic pathways. This narrative review critically evaluates the pharmacological efficacy, mechanisms of action, and safety profiles of selected natural compounds, including psilocybin-related tryptamines,

Indexed as

AgaricalesBiological ProductsMental DisordersPlants, MedicinalAnimalsHumansBiological ProductsanxietydepressionergothioneineHericium erinaceusHypericum perforatumibotenic acidmedicinal plantsmuscimolneuroinflammationneuroprotectionpsilocinpsilocybinpsychedelic therapypsychiatric disorderstryptaminesValeriana officinalis

Identifiers

PMID42738789
PMCPMC13567430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.